A Phase II dose-escalation study of sorafenib was conducted in 44 evaluable patients, 19 of whom received prior therapy. [82] The initial dosage was 400 mg twice daily for 28 days, followed by 600 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback